- Adherence among chronic disease patients can lead to big savings
- Novo Nordisk's Victoza helps patients achieve blood-sugar control when switching from exenatide or sitagliptin
- Fatty liver may impose diabetes risk
- Novo Nordisk wins 2010 Good Design Award for NovoPen Echo
- Sanofi presents study data at American Diabetes Association’s 71st Scientific Sessions
FRANKLIN LAKES, N.J. Becton, Dickinson and Co. has launched what the company calls the world's smallest insulin pen needle.
The BD Ultra-Fine Nano provides glucose control of typical longer insulin pen needles but with less pain upon injection, BD said.
“BD is committed to helping improve the injection experience for the millions of people who live with diabetes, as demonstrated by our long history of innovative firsts — the first insulin syringe in 1924, the first 5 mm pen needle in 1999 and the now the world’s first 4 mm pen needle, the BD Nano,” said Linda Tharby, president of BD Medical diabetes care division. “We are confident that this tiny needle can have a big impact by easing diabetes patients’ transition and ongoing adherence to injectable drug therapy regimens — a key element in helping to reduce the disease’s deadly, debilitating and costly complications.”